Physicochemical Properties
| Molecular Formula | C20H19CLN2O3S |
| Molecular Weight | 402.894462823868 |
| Exact Mass | 402.08 |
| CAS # | 151227-08-6 |
| PubChem CID | 9887401 |
| Appearance | White to off-white solid powder |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 27 |
| Complexity | 533 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | C([C@@H]1NCC2SC3C=CC=CC=3C=2C1)(=O)NCC1C=CC2OCOC=2C=1.Cl |
| InChi Key | IPRJDKMLMDPMBH-XFULWGLBSA-N |
| InChi Code | InChI=1S/C20H18N2O3S.ClH/c23-20(22-9-12-5-6-16-17(7-12)25-11-24-16)15-8-14-13-3-1-2-4-18(13)26-19(14)10-21-15;/h1-7,15,21H,8-11H2,(H,22,23);1H/t15-;/m1./s1 |
| Chemical Name | (3R)-N-(1,3-benzodioxol-5-ylmethyl)-1,2,3,4-tetrahydro-[1]benzothiolo[2,3-c]pyridine-3-carboxamide;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | AP521 is an agonist of human 5-HT1A receptor. The IC50 for 5-HT1A (rat), 5-HT1A (human), 5-HT1B (rat) and 5 are 135, 94, 254, 5530 and 418 correspondingly. , 422 and 198 nM for -HT1B (human), 5-HT1D (human), 5-HT5a (human) and 5-HT7 (rat) correspondingly. AP521 also lowers forskolin-induced cAMP buildup from 10 nM to 10 μM [1]. |
| ln Vivo | The amount of shocks received between doses of 0.5 and 10 mg/kg was considerably enhanced by AP521 [F(5,105)=4.46, P<0.01]. The freezing period may be considerably shortened by oral treatment of 3 and 10 mg/kg AP521 [F(3,60)=2.89, P<0.05]. The time to open the arm was nearly twice as long with AP521 as it was with the vehicle-treated group [F(3, 36)=4.21, P<0.05 for AP521]. It seems that AP521's anxiolytic-like effects are dose-related. After 0.5 to 1 hour of treatment, AP521 at 10 mg/kg dramatically raised extracellular 5-HT levels in the medial prefrontal cortex (mPFC). Extracellular 5-HT levels were somewhat raised by AP521 at 3 mg/kg, however this rise was not statistically significant [1]. |
| References |
[1]. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. J Pharmacol Sci. 2015 Jan;127(1):109-16. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~25 mg/mL (~62.05 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4821 mL | 12.4103 mL | 24.8207 mL | |
| 5 mM | 0.4964 mL | 2.4821 mL | 4.9641 mL | |
| 10 mM | 0.2482 mL | 1.2410 mL | 2.4821 mL |